Lawler S D, Fisher R A
Placenta. 1987 Mar-Apr;8(2):195-9. doi: 10.1016/0143-4004(87)90022-1.
The HLA and ABO systems were studied in patients with complete hydatidiform mole (CHM). The study confirmed that CHM can immunize the patient against paternally derived HLA-ABC antigens. In patients who required subsequent treatment for trophoblastic tumours the frequency of antibody detection was much higher (10/14) at the time of treatment than it had been at the time of evacuation (2/14). The source of immunogen was considered to be the stroma of the placental villi. It was demonstrated that in a series of 82 CHMs none of the 25 patients mated to a husband of the same ABO group as her own required treatment for postmole trophoblastic tumours. Among unlike matings 17 out of 57 of the patients required treatment. Thus it appears that trophoblastic proliferation after evacuation of mole is favoured by an ABO difference between maternal environment and the molar tissue.
对完全性葡萄胎（CHM）患者的人类白细胞抗原（HLA）系统和ABO血型系统进行了研究。该研究证实，完全性葡萄胎可使患者对父系来源的HLA - ABC抗原产生免疫。在需要后续治疗滋养细胞肿瘤的患者中，治疗时抗体检测频率（10/14）远高于清宫时（2/14）。免疫原的来源被认为是胎盘绒毛的间质。结果表明，在82例完全性葡萄胎患者中，与丈夫血型相同（ABO血型）的25例患者中，无一例需要治疗葡萄胎后滋养细胞肿瘤。在血型不同的配偶组合中，57例患者中有17例需要治疗。因此，似乎清宫后滋养细胞增殖受到母体环境与葡萄胎组织之间ABO血型差异的促进。
